TrialJAMA oncology2020

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial.

Alexander M M Eggermont et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.